Stack Financial Management Inc Makes New $29.13 Million Investment in AbbVie Inc. $ABBV

Posted by Stanley Muller on Aug 22nd, 2026

Stack Financial Management Inc acquired a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) during the second quarter, Holdings Channel.com reports. The firm acquired 115,754 shares of the company’s stock, valued at approximately $29,128,000. AbbVie comprises approximately 2.3% of Stack Financial Management Inc’s portfolio, making the stock its 13th biggest holding.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Croban raised its position in shares of AbbVie by 2.5% in the second quarter. Croban now owns 7,077 shares of the company’s stock valued at $1,781,000 after purchasing an additional 172 shares during the period. Beacon Bank & Trust boosted its holdings in shares of AbbVie by 5.2% during the 2nd quarter. Beacon Bank & Trust now owns 4,149 shares of the company’s stock worth $1,044,000 after buying an additional 204 shares during the period. Sterling Group Wealth Management LLC bought a new stake in shares of AbbVie during the 2nd quarter worth $204,000. TSA Wealth Managment LLC acquired a new position in AbbVie in the 2nd quarter valued at $233,000. Finally, Bryn Mawr Trust Advisors LLC raised its holdings in AbbVie by 3.8% in the 2nd quarter. Bryn Mawr Trust Advisors LLC now owns 8,879 shares of the company’s stock worth $2,234,000 after acquiring an additional 326 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Up 1.4%

NYSE ABBV opened at $265.62 on Friday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The company has a market capitalization of $469.29 billion, a price-to-earnings ratio of 75.03, a PEG ratio of 0.87 and a beta of 0.30. The stock’s 50 day moving average is $248.48 and its two-hundred day moving average is $227.49.

AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts predict that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Insider Transactions at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the topic of several research analyst reports. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Citigroup boosted their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Wells Fargo & Company increased their target price on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $275.95.

View Our Latest Stock Report on AbbVie

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.